CLAIMS

1- Use of agomelatine, or *N*-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, or one of its hydrates, crystalline forms or addition salts with a pharmaceutically acceptable acid or base, in obtaining a medicament intended for the treatment of Obsessive-Compulsive Disorder (OCD).

2- Use according to claim 1, characterised in that the agomelatine is obtained in crystalline form II.

3- Pharmaceutical compositions comprising agomelatine, or one of its hydrates, crystalline forms or addition salts with a pharmaceutically acceptable acid or base, on its own or in combination with one or more pharmaceutically acceptable excipients, for use in the manufacture of a medicament intended for the treatment of Obsessive-Compulsive Disorder (OCD).

4- Pharmaceutical composition according to claim 3, characterised in that the agomelatine is obtained in crystalline form II.

5- Agomelatine, or *N*-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, or one of its hydrates, crystalline forms or addition salts with a pharmaceutically acceptable acid or base, for use in the treatment of Obsessive-Compulsive Disorder (OCD).

6- Crystalline form II of agomelatine for use in the treatment of Obsessive-Compulsive Disorder (OCD).

The claims defining the invention are as follows:

1. Use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, or one of its hydrates, crystalline forms or addition salts with a pharmaceutically acceptable acid or base, in the manufacture of a medicament for the treatment of Obsessive-Compulsive Disorder (OCD).

2. The use according to claim 1, wherein the agomelatine is crystalline form II agomelatine.

3. Use of a pharmaceutical composition comprising agomelatine, or one of its hydrates, crystalline forms or addition salts with a pharmaceutically acceptable acid or base, on its own or in combination with one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for the treatment of Obsessive-Compulsive Disorder (OCD).

4. The pharmaceutical composition according to claim 3, wherein the agomelatine is crystalline form II agomelatine.

5. A method for the treatment of Obsessive-Compulsive Disorder (OCD) comprising administering to a patient suffering from OCD agomelatine, or one of its hydrates, crystalline forms or addition salts with a pharmaceutically acceptable acid or base, or a pharmaceutical composition containing agomelatine or one of its hydrates, crystalline forms or addition salts with a pharmaceutically acceptable acid or base, in a sufficient amount to alleviate the OCD.

6. The method according to claim 5, wherein the agomelatine is crystalline form II agomelatine.